Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
Active, not recruiting · Not applicable · NCT04905069
Conditions: Prostate Cancer
At a glance
- Research payments reported, 2025
- $35,993
- U.S. investigators named
- 5
- Sites paid
- 6
- Planned or actual enrollment
- 500
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- SpaceOAR Vue System (device)
- Dates
- Started 2021-12-21; completion 2030-12
- Results posted
- Not yet
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.
From ClinicalTrials.gov, last updated 2026-10-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $35,993 in research payments for this study in 2025 (20 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alexander Engelman, M.D. Radiation Oncology · Tampa, FL
- Ronald C. Chen, M.D. Radiation Oncology · Kansas City, KS
- Krisha J. Howell, M.D. Radiation Oncology · Troy, MI
- Glen Gejerman, MD Radiation Oncology · Hackensack, NJ
- Adam C. Olson, M.D. Radiation Oncology · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Summit Medical Group PA $11,617
- University of Kansas Medical Center Research Institute Inc $11,419
- Profound Research LLC $6,650
- University of Pittsburgh Cancer Institute Cancer Services $3,747
- Florida Urology PArtners LLP $1,910
- Genesiscare USA of Florida LLC $650
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.